Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300 mg per day) due to intolerance, in comparison to optimal-dose imatinib (≥300 mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan-Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420 days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720 days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.
Imatinib was the first BCR - ABL tyrosine kinase inhibitor to become clinically available . In this study , we retrospectively evaluated the long - term efficacy of low - dose imatinib ( final maintenance dose < 300 mg per day ) due to intolerance , in comparison to optimal - dose imatinib ( ≥300 mg per day ) in patients with Philadelphia chromosome - positive chronic myeloid leukemia in the chronic phase . The Kaplan - Meier estimates of the median time to complete cytogenetic response , major molecular response , and complete molecular response were longer for 31 patients receiving low - dose imatinib ( 360 , 1360 , and 1420 days , respectively ) than 74 patients receiving optimal - dose imatinib ( 170 , 420 , and 720 days , respectively ) . However , the differences in response shrank over time and progression - free survival were comparable between the two groups . These findings suggest that long - term treatment with low - dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose .
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?
What tyrosine kinase , involved in a Philadelphia- chromosome positive chronic myelogenous leukemia , is the target of Imatinib ( Gleevec ) ?
BCR-ABL
BCR-ABL